OTCMKTS:ALPMY Astellas Pharma (ALPMY) Stock Price, News & Analysis $10.96 -0.07 (-0.67%) As of 08/27/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Astellas Pharma Stock (OTCMKTS:ALPMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astellas Pharma alerts:Sign Up Key Stats Today's Range$10.84▼$10.9650-Day Range$9.23▼$11.5252-Week Range$8.37▼$13.14Volume91,469 shsAverage Volume122,172 shsMarket Capitalization$19.83 billionP/E Ratio36.53Dividend Yield3.10%Price TargetN/AConsensus RatingN/A Company Overview Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan. Read More Receive ALPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALPMY Stock News HeadlinesShort Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Declines By 46.6%August 18, 2025 | americanbankingnews.comAstellas Pharma Inc. ADR Financials | ALPMY | Barron'sAugust 14, 2025 | barrons.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.August 28 at 2:00 AM | Timothy Sykes (Ad)Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancerAugust 12, 2025 | msn.comPfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer?August 12, 2025 | msn.comPfizer and Astellas Advance Prostate Cancer Study with Promising Drug ComboJuly 31, 2025 | msn.comAstellas Shares Jump After Profits Fueled by Strong Drug SalesJuly 30, 2025 | bloomberg.comAstellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"July 16, 2025 | prnewswire.comSee More Headlines ALPMY Stock Analysis - Frequently Asked Questions How have ALPMY shares performed this year? Astellas Pharma's stock was trading at $9.66 at the beginning of 2025. Since then, ALPMY shares have increased by 13.5% and is now trading at $10.96. How were Astellas Pharma's earnings last quarter? Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its earnings results on Wednesday, July, 30th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.14 by $0.26. The business earned $3.41 billion during the quarter, compared to the consensus estimate of $3.20 billion. Astellas Pharma had a net margin of 4.34% and a trailing twelve-month return on equity of 19.76%. When did Astellas Pharma's stock split? Astellas Pharma shares split on Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split. Does Astellas Pharma have any subsidiaries? Astellas Pharma subsidiaries include Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more. How do I buy shares of Astellas Pharma? Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/30/2025Today8/27/2025Next Earnings (Estimated)10/29/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:ALPMY CIK1446390 Webwww.astellas.com Phone(133) 244-3000FaxN/AEmployees14,754Year Founded1923Profitability EPS (Trailing Twelve Months)$0.30 Trailing P/E Ratio36.53 Forward P/E Ratio26.10 P/E GrowthN/ANet Income$334.93 million Net Margins4.34% Pretax Margin1.63% Return on Equity19.76% Return on Assets8.75% Debt Debt-to-Equity Ratio0.37 Current Ratio1.13 Quick Ratio0.85 Sales & Book Value Annual Sales$12.56 billion Price / SalesN/A Cash Flow$1.79 per share Price / Cash Flow6.13 Book Value$5.52 per share Price / Book1.99Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.26 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:ALPMY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.